Egham, United Kingdom

Alberto Malerba



Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alberto Malerba: Innovator in RNA Interference for Oculopharyngeal Muscular Dystrophy

Introduction

Alberto Malerba is a notable inventor based in Egham, GB. He has made significant contributions to the field of medical research, particularly in the treatment of oculopharyngeal muscular dystrophy (OPMD). His innovative work focuses on developing RNA interference (RNAi) reagents that offer new hope for individuals suffering from this condition.

Latest Patents

Malerba holds a patent for "Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof." This patent encompasses RNAi reagents designed to treat OPMD, along with compositions that utilize these reagents. The application of his invention aims to provide therapeutic options for individuals affected by OPMD or those predisposed to the disease.

Career Highlights

Alberto Malerba is associated with Benitec Biopharma Limited, a company dedicated to advancing gene silencing technologies. His work at the company has positioned him as a key player in the development of innovative treatments for genetic disorders. His expertise in RNAi technology has been instrumental in pushing the boundaries of therapeutic possibilities.

Collaborations

Malerba has collaborated with esteemed colleagues, including David A Suhy and Michael Graham. These partnerships have fostered a collaborative environment that enhances the research and development of effective treatments for OPMD.

Conclusion

Alberto Malerba's contributions to the field of RNA interference represent a significant advancement in the treatment of oculopharyngeal muscular dystrophy. His innovative approach and dedication to medical research continue to inspire progress in the fight against genetic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…